Search Result

Results for "

Anxiety model

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (7) Adenosine Receptor (1) Adrenergic Receptor (2) Apoptosis (2) Bacterial (1) Caspase (2) CRFR (4) CXCR (1) Dopamine Receptor (3) Drug Intermediate (2) Endogenous Metabolite (1) FAAH (1) Fat Mass and Obesity-associated Protein (FTO) (1) GABA Receptor (1) Heme Oxygenase (HO) (1) iGluR (3) Interleukin Related (1) Keap1-Nrf2 (1) MCHR1 (GPR24) (2) Melanocortin Receptor (1) mGluR (3) nAChR (1) Neurokinin Receptor (1) Opioid Receptor (1) Orexin Receptor (OX Receptor) (2) Reference Standards (5) Serotonin Transporter (2) TNF Receptor (1) TSPO (2) Vasopressin Receptor (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (2) Endocrinology (5) Infection (1) Inflammation/Immunology (5) Metabolic Disease (4) Neurological Disease (33)

By Targets:

5-HT Receptor (7)

Adenosine Receptor (1)

Adrenergic Receptor (2)

Apoptosis (2)

Bacterial (1)

Caspase (2)

CRFR (4)

CXCR (1)

Dopamine Receptor (3)

Drug Intermediate (2)

Endogenous Metabolite (1)

FAAH (1)

Fat Mass and Obesity-associated Protein (FTO) (1)

GABA Receptor (1)

Heme Oxygenase (HO) (1)

iGluR (3)

Interleukin Related (1)

Keap1-Nrf2 (1)

MCHR1 (GPR24) (2)

Melanocortin Receptor (1)

mGluR (3)

nAChR (1)

Neurokinin Receptor (1)

Opioid Receptor (1)

Orexin Receptor (OX Receptor) (2)

Reference Standards (5)

Serotonin Transporter (2)

TNF Receptor (1)

TSPO (2)

Vasopressin Receptor (1)

By Research Areas:

Cancer (1)

Cardiovascular Disease (2)

Endocrinology (5)

Infection (1)

Inflammation/Immunology (5)

Metabolic Disease (4)

Neurological Disease (33)

Inhibitors & Agonists

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103377

Antalarmin hydrochloride Maximum Cited Publications 6 Publications Verification	CRFR	Inflammation/Immunology Endocrinology
Antalarmin (hydrochloride) is an oral active non-peptide corticotropin-releasing hormone receptor 1 (CRHR1) antagonist with a K_i of 1 nM. Antalarmin hydrochloride suppresses CRH-induced ACTH secretion and blocks CRH and novelty induced anxiety-like behavior in animal models. Antalarmin hydrochloride produces anti-inflammatory effects in arthritis models, and suppresses stress-induced gastric ulceration related to irritable bowel syndrome .

HY-15527

Emapunil 4 Publications Verification AC-5216; XBD-173	TSPO	Neurological Disease Metabolic Disease
Emapunil (AC-5216), an orally active and selective TSPO (a mitochondrial benzodiazepine receptor) ligand, produces anti-anxiety and antidepressant-like effects in various animal models .

HY-100834

5,7-Dichlorokynurenic acid 1 Publications Verification 5,7-DCKA	iGluR	Neurological Disease
5,7-Dichlorokynurenic acid (5,7-DCKA) is a selective and competitive antagonist of the glycine site on NMDA receptor with a K_B of 65 nM. 5,7-Dichlorokynurenic acid reduces NMDA-induced neuron injury. 5,7-Dichlorokynurenic acid increases social interaction time, increases open arm exploration time, disinhibits suppressed conflict responding in rodent models. 5,7-Dichlorokynurenic acid exhibits anxiolytic-like activity in rodent models and supports exploration of glycine’s role in NMDA receptor-mediated synaptic transmission .

HY-172236

Soclenicant BNC210; IW-2143	nAChR	Neurological Disease
Soclenicant (BNC210) is an orally active α7 nAChR negative alteration modulator (NAM) with no apparent side effects. Soclenicant exhibits acute anxiolytic activity in rodent models of anxiety. Soclenicant inhibits rat and human α7 nAChR currents (in stably transfected cell lines) induced by acetylcholine, nicotine, choline, and the a7-specific agonist PNU-282987 (HY-12560A) with IC₅₀ values in the range of 1.2 to 3 μM. Soclenicant can be used in studies of anxiety, trauma, and stressor-related disorders .

HY-W009123

Erucamide cis-13-Docosenamide	Endogenous Metabolite Bacterial	Infection Neurological Disease
Erucamide is an orally active, blood-brain barrier-permeable TMEM19 ligand and T3SS inhibitor. Erucamide exerts retinal neuroprotective effects in mouse models of retinal degeneration. Erucamide attenuates depression- and anxiety-like behaviors in mice.\n\nErucamide binds to the conserved hydrophobic pocket in HrcC, disrupts its outer membrane localization, and blocks T3SS-mediated effector protein secretion in Gram-negative pathogenic bacteria. Erucamide enhances the antimicrobial immunity of plants against pathogenic bacteria. Erucamide can be used in research related to retinitis pigmentosa, anxiety and depression, bacterial wilt, and bacterial blight .

HY-P1108

Astressin 2B 1 Publications Verification	CRFR	Neurological Disease Inflammation/Immunology
Astressin 2B is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC₅₀=0.57 nM). Astressin 2B blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .

HY-P1108A

Astressin 2B TFA 1 Publications Verification	CRFR	Neurological Disease Inflammation/Immunology
Astressin 2B TFA is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC₅₀=0.57 nM). Astressin 2B TFA blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B TFA reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B TFA also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B TFA mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B TFA is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .

HY-10900

TCS 1102 1 Publications Verification	Orexin Receptor (OX Receptor)	Neurological Disease Endocrinology
TCS 1102 is a potent, dual orexin receptor antagonist, with Ki values of 0.2 nM and 3 nM for OX2 and OX1 receptors, respectively. TCS 1102 demonstrates excellent blood-brain barrier penetrability and moderate bioavailability in rats .

HY-W017424

2-Aminobenzothiazole	Drug Intermediate Caspase Apoptosis	Neurological Disease Cancer
2-Aminobenzothiazole acts as a caspase 3/7 activator, an anticancer cytotoxic agent, and also exhibits neurotoxicity. 2-Aminobenzothiazole drives the apoptotic pathway by activating caspase 3/7, induces mitochondrial inner membrane depolarization, and triggers both early and late apoptosis via a caspase-dependent pathway. In zebrafish models, 2-Aminobenzothiazole induces oxidative damage in brain tissues and inhibits genes related to GABA and 5-HT synthesis pathways. Long-term exposure to 2-Aminobenzothiazole impairs motor ability, social behavior, anxiety-like state and cognitive function. 2-Aminobenzothiazole can be used in studies of human laryngeal carcinoma and related neurotoxicity .

HY-107624

ATC0175 1 Publications Verification	MCHR1 (GPR24)	Neurological Disease
ATC0175 is a potent, selective and orally active melanin-concentrating hormone 1 recepter antagonist with IC₅₀s of 13.5, >10000 nM for MCH1R, MCH2R, respectively. ATC0175 shows antidepressant effects and anxiolytic effects in animal models. ATC0175 has the potential for the research of depression and/or anxiety disorders .

HY-117820

TASP0390325	Vasopressin Receptor	Cardiovascular Disease Neurological Disease
TASP0390325 is a high affinity and orally active arginine vasopressin receptor 1B (V1B receptor) antagonist with antidepressant and anxiolytic activities .

HY-103571

VU0285683	mGluR	Neurological Disease
VU0285683 is a selective mGluR5 positive allosteric modulator (PAM). VU0285683 has anxiolytic-like activity in rodent models for anxiety .

HY-112567

TRR469	Adenosine Receptor	Neurological Disease
TRR469 is a positive allosteric modulator of the A₁ adenosine receptor (A₁AR). TRR469 significantly increases the affinity of 2-chloro N(6)-cyclopentyladenosine (CCPA) for A₁AR, increasing the number of receptors recognized by the agonist radioligand [³H]-CCPA. TRR469 shows significant effects in both anxiety and pain models. TRR469 can be used to study anxiety disorders and pain management .

HY-116266

RS 67333	5-HT Receptor	Others
RS 67333 is a 5-HT4R agonist with stress-preventive activity. RS 67333 attenuates stress-induced body weight changes and prevents depression- and anxiety-like behaviors in two mouse strains tested in different stress models.

HY-P10405A

TAT-D1 peptide acetate	Dopamine Receptor	Neurological Disease
TAT-D1 peptide acetate is a dopamine D1-D2 receptor heterodimer inhibitor. TAT-D1 peptide acetate disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide acetate produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide acetate can be used in the research of psychostimulant addiction, depression and anxiety disorders .

HY-138693

ST4070	FAAH	Neurological Disease
ST4070 is a potent, orally active, and selective reversible fatty acid amide hydrolase (FAAH) inhibitor. ST4070 increases endocannabinoid (eCB) brain levels and counteracts neuropathic pain in animal models. ST4070 enhances the endogenous eCB tone in specific brain regions engaged in emotional control, and induces remarkable anxiolytic-like behaviours in rodents. ST4070 can be used for neuropathic pain and anxiety disorders research .

HY-105998

AVN-211	5-HT Receptor	Neurological Disease
AVN-211 (CD-008-0173) is a selective and orally active 5HT₆R antagonist with an IC₅₀ of 2.34 nM and a K_i of 1.09 nM. AVN-211 exhibits 5K-fold higher 5HT₆R selectivity over other 65 receptors, enzymes, and ion channels. AVN-211 significantly improves cognitive and anxiety behaviors in various AD animal models, and has good safety profiles. AVN-211 can be used for the study of Alzheimer's dementia .

HY-W794785

WAY 208466	5-HT Receptor	Neurological Disease
WAY 208466 is a selective 5-HT6 receptor agonist with an EC₅₀ of 7.3 nM. WAY-208466 increases GABA levels following both acute and chronic administration in the dorsolateral frontal cortex of rat models with stereotaxic surgery. WAY 208466 can be used for anxiety-related disorders like obsessive compulsive disorder (OCD) research .

HY-P10405

TAT-D1 peptide	Dopamine Receptor	Neurological Disease
TAT-D1 peptide is a dopamine D1-D2 receptor heterodimer inhibitor. TAT-D1 peptide disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide can be used in the research of psychostimulant addiction, depression and anxiety disorders .

HY-118152

Org-12962	5-HT Receptor	Neurological Disease Metabolic Disease
Org-12962 is a potent, selective and brain-penetrant and 5-HT_2C receptor agonist with a pEC₅₀ value of 7.01. Org-12962 also exhibits high effacy for the 5-HT_2A and 5-HT_2B receptor with pEC₅₀s of 6.38 and 6.28, respectively .Org-12962 displays antiaversive effects in a rat model of panic-like anxiety .

HY-174395

CD-10	Keap1-Nrf2 Interleukin Related Heme Oxygenase (HO)	Neurological Disease
CD-10 is an orally active and BBB-penatrable Keap1-Nrf2 protein-protein interaction (PPI) inhibitor. CD-10 binds to Keap1 with a K_D value of 193 nM. CD-10 exhibits potent anti-oxidative and anti-inflammatory effects through Keap1-Nrf2 pathway activation, evidenced by reduced levels of MDA, IL-4, IL-10 and increased expression of HO-1. CD-10 effectively alleviated anxiety and depressive behaviors and restored serum neurotransmitter levels by promoting Nrf2 nuclear translocation in the chronic unpredictable mild stress (CUMS) mouse model. CD-10 can be used for the study of depression.

HY-15527R

Emapunil (Standard) AC-5216 (Standard); XBD-173 (Standard)	Reference Standards TSPO	Neurological Disease Metabolic Disease
Emapunil (Standard) is the analytical standard of Emapunil. This product is intended for research and analytical applications. Emapunil (AC-5216), an orally active and selective TSPO (a mitochondrial benzodiazepine receptor) ligand, produces anti-anxiety and antidepressant-like effects in various animal models .

HY-120167

YM-44778	Neurokinin Receptor	Neurological Disease Inflammation/Immunology
YM-44778 is a neurokinin receptor antagonist. The _pK_i values for NK1, NK2 and NK3 are 8.08, 8.55 and 8.24, respectively. YM-44778 inhibits the increase of bladder pressure induced by substance [Sar9,Met(O2)11] -P (HY-P1012) in anestheticized rats .

HY-120144

SR-8993	Opioid Receptor	Neurological Disease
SR-8993 is a highly selective nociceptin receptor agonist that can penetrate the blood-brain barrier and has the activity of reducing alcohol intake and relieving withdrawal anxiety. SR-8993 has shown mild anxiolytic effects in animal models and can effectively reverse anxiety caused by acute alcohol withdrawal. SR-8993 further reduces restricted drinking, operant responses for alcohol, and increased drinking induced by long-term intermittent exposure to alcohol. SR-8993 also reduces stress- and cue-related alcohol-seeking relapse .

HY-103377R

Antalarmin hydrochloride (Standard)	Reference Standards CRFR	Inflammation/Immunology Endocrinology
Antalarmin (hydrochloride) (Standard) is the analytical standard of Antalarmin (hydrochloride). This product is intended for research and analytical applications. Antalarmin (hydrochloride) is an oral active non-peptide corticotropin-releasing hormone receptor 1 (CRHR1) antagonist with a Ki of 1 nM. Antalarmin hydrochloride suppresses CRH-induced ACTH secretion and blocks CRH and novelty induced anxiety-like behavior in animal models. Antalarmin hydrochloride produces anti-inflammatory effects in arthritis models, and suppresses stress-induced gastric ulceration related to irritable bowel syndrome .

HY-108041

MGS 0210 BCI 838	mGluR	Neurological Disease
MGS 0210 (BCI 838) is an orally active metabolite of glutamate receptor 2/3 (mGluR2/3) agonists. MGS 0210 improves amnesia and reduces anxiety in APP mice. MGS 0210 improves PTSD-related behaviors in a mouse model of post-traumatic stress disorder (PTSD). MGS 0210 can be used in research on neurological disorders such as Alzheimer's disease and major depressive disorder .

HY-21994

Org-12962 hydrochloride	5-HT Receptor	Neurological Disease
Org 12962 hydrochloride is a potent, selective and efficacious 5-HT_2C receptor agonist and exhibits pEC₅₀ values of 7.01, 6.38 and 6.28 for 5-HT_2C, 5-HT_2A and 5-HT_2A, respectively. Org 12962 hydrochloride is effective in panic-like anxiety animal model .

HY-W017424R

2-Aminobenzothiazole (Standard)	Reference Standards Apoptosis Drug Intermediate Caspase	Others
2-Aminobenzothiazole (Standard) is the analytical standard of 2-Aminobenzothiazole. This product is intended for research and analytical applications. 2-Aminobenzothiazole acts as a caspase 3/7 activator, an anticancer cytotoxic agent, and also exhibits neurotoxicity. 2-Aminobenzothiazole drives the apoptotic pathway by activating caspase 3/7, induces mitochondrial inner membrane depolarization, and triggers both early and late apoptosis via a caspase-dependent pathway. In zebrafish models, 2-Aminobenzothiazole induces oxidative damage in brain tissues and inhibits genes related to GABA and 5-HT synthesis pathways. Long-term exposure to 2-Aminobenzothiazole impairs motor ability, social behavior, anxiety-like state and cognitive function. 2-Aminobenzothiazole can be used in studies of human laryngeal carcinoma and related neurotoxicity .

HY-100834A

5,7-Dichlorokynurenic acid sodium 5,7-DCKA sodium	iGluR	Neurological Disease
5,7-Dichlorokynurenic acid (5,7-DCKA) sodium is a selective and competitive antagonist of the glycine site on NMDA receptor with a K_B of 65 nM. 5,7-Dichlorokynurenic acid sodium reduces NMDA-induced neuron injury. 5,7-Dichlorokynurenic acid sodium increases social interaction time, increases open arm exploration time, disinhibits suppressed conflict responding in rodent models. 5,7-Dichlorokynurenic acid sodium exhibits anxiolytic-like activity in rodent models and supports exploration of glycine’s role in NMDA receptor-mediated synaptic transmission .

HY-131286

Talaglumetad LY-544344	mGluR	Neurological Disease
Talaglumetad (LY-544344) is an orally active prodrug of Eglumegad (HY-18941) and a metabotropic glutamate receptor 2/3 (mGluR2/3) agonist. Talaglumetad undergoes transmembrane transport via the intestinal peptide transporter hPepT1, and is enzymatically hydrolyzed to produce L-alanine and the parent drug Eglumegad after entering the body. Talaglumetad can be used in research related to metabotropic glutamate receptor 2-associated neurological systems .

HY-107624R

ATC0175 (Standard)	Reference Standards MCHR1 (GPR24)	Neurological Disease
ATC0175 (Standard) is the analytical standard of ATC0175 (HY-107624). This product is intended for research and analytical applications. ATC0175 is a potent, selective and orally active melanin-concentrating hormone 1 recepter antagonist with IC₅₀s of 13.5, >10000 nM for MCH1R, MCH2R, respectively. ATC0175 shows antidepressant effects and anxiolytic effects in animal models. ATC0175 has the potential for the research of depression and/or anxiety disorders .

HY-P0267A

Melanotan (MT)-II acetate	Melanocortin Receptor	Neurological Disease Metabolic Disease Endocrinology
Melanotan (MT)-II acetate is a melanocortin receptor agonist that crosses the blood-brain barrier. Melanotan (MT)-II acetate activates melanocortin receptor 3 and melanocortin receptor 4, and stimulates the release of central endogenous oxytocin. Melanotan (MT)-II acetate reverses recognition memory impairment, increased anxiety levels and reduced exploratory tendency in zebrafish exposed to short-term high-fat diet. Melanotan (MT)-II acetate improves impaired social behavior indicators in mouse models of autism spectrum disorder. Melanotan (MT)-II acetate induces weight loss, reduces food intake and exerts anorectic effects. Melanotan (MT)-II acetate increases intracavernous pressure and erectile activity in brown rats. Melanotan (MT)-II acetate can be used in studies related to memory impairment, anxiety, reduced exploratory behavior, autism spectrum disorder, obesity and erectile dysfunction .

HY-183325

FTO-IN-17	Fat Mass and Obesity-associated Protein (FTO) CXCR TNF Receptor	Neurological Disease
FTO-IN-17 is an orally active and brain-penetrant FTO (m₆A RNA demethylase) inhibitor with an IC₅₀ of 1.1 μM. FTO-IN-17 stably binds the FTO catalytic pocket. FTO-IN-17 protects against Aβ1-42-induced toxicity while increasing global m₆A levels and dampening pro-inflammatory gene (CXCL10, TNF-α) expression. FTO-IN-17 ameliorates anxiety-like behavior and rescues hippocampal-dependent spatial, recognition memory and neuroinflammation in Alzheimer's disease mice models .

HY-10900R

TCS 1102 (Standard)	Reference Standards Orexin Receptor (OX Receptor)	Neurological Disease Endocrinology
TCS 1102 (Standard) is the analytical standard of TCS 1102 (HY-10900). This product is intended for research and analytical applications. TCS 1102 is a potent, dual orexin receptor antagonist, with K_i values of 0.2 nM and 3 nM for OX2 and OX1 receptors, respectively. TCS 1102 demonstrates excellent blood-brain barrier penetrability and moderate bioavailability in rats .

HY-15080

GYKI 53405 LY 293606	iGluR	Cardiovascular Disease Neurological Disease
GYKI 53405 is a non-competitive, orally active AMPA receptor antagonist. GYKI 53405 shows no significant binding affinity for GABA_A, GABA_B or benzodiazepine receptors. GYKI 53405 increases self-grooming behavior, induces wet dog-like shakes, reduces spontaneous activity, produces anxiolytic-like behavior, reverses the anxiogenic effect induced by mCPP, inhibits locomotor activity, suppresses sound-induced and maximal electroshock-induced seizures, prolongs survival in global cerebral ischemia models, and exhibits sustained anticonvulsant effects at doses below the sedation threshold. GYKI 53405 can be used in research related to absence epilepsy, anxiety disorders and global cerebral ischemia .

HY-181878

Z8779877149 Z7149	Serotonin Transporter Adrenergic Receptor 5-HT Receptor	Neurological Disease
Z8779877149 (Z7149) is a blood-brain barrier-permeable multi-target ligand that targets SERT (K_i=198 nM), α2A adrenergic receptor (K_i=180 nM; EC₅₀=440 nM) and 5-HT_2A receptor (EC₅₀=172 nM, E_max=76%). Z8779877149 inhibits 5-HT reuptake and activates G_i and Gq protein signaling pathways, respectively. Z8779877149 effectively alleviates pain responses as well as depression- and anxiety-like behaviors, while exhibiting favorable safety without inducing sedation or motor impairment. Z8779877149 is available for the research of pain, depression and anxiety disorders .

HY-180372

CSP-2503	5-HT Receptor Adrenergic Receptor GABA Receptor Serotonin Transporter Dopamine Receptor	Neurological Disease
CSP-2503 is a potent and selective 5-HT_1A receptor agonist , with an EC₅₀ of 0.15 μM and a K_i of 4.1 nM. CSP-2503 exhibits excellent selectivity over α1-adrenoceptors (K_i > 1000 nM), 5-HT₄ receptors, and benzodiazepine receptors. CSP-2503 inhibits cAMP increase in vitro and exhibits anxiolytic activity in vivo. CSP-2503 can be used for the research of anxiety-related disorders .

Cat. No.	Product Name	Target	Research Area